These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32328845)

  • 1. Advances in the Treatment of Cardiac Amyloidosis.
    Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
    Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
    Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
    Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Care of Patients with Cardiac Amyloidosis.
    Itzhaki Ben Zadok O; Kornowski R
    Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL; Maurer MS
    JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
    Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
    Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
    Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
    Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
    Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
    Brito D; Albrecht FC; de Arenaza DP; Bart N; Better N; Carvajal-Juarez I; Conceição I; Damy T; Dorbala S; Fidalgo JC; Garcia-Pavia P; Ge J; Gillmore JD; Grzybowski J; Obici L; Piñero D; Rapezzi C; Ueda M; Pinto FJ
    Glob Heart; 2023; 18(1):59. PubMed ID: 37901600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy.
    Capustin M; Frishman WH
    Cardiol Rev; 2021 Sep-Oct 01; 29(5):263-273. PubMed ID: 34397539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.
    Ioannou A; Fontana M; Gillmore JD
    Heart Int; 2023; 17(1):27-35. PubMed ID: 37456349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Illustrative review of cardiac amyloidosis by multimodality imaging.
    Tanaka H
    Heart Fail Rev; 2023 Jan; 28(1):113-122. PubMed ID: 35474404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloidosis in Heart Failure.
    Ihne S; Morbach C; Obici L; Palladini G; Störk S
    Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.
    Kaiser ME; Lewis TJ
    Cureus; 2023 Dec; 15(12):e50527. PubMed ID: 38098740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.